Innovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020
January 16, 2020 12:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the...
Grant Opportunity To Improve Prediction And Prevention Of IBD
January 07, 2020 10:55 ET
|
Kenneth Rainin Foundation
Oakland, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation invites Letters of Inquiry for its Innovator Awards Program from January 15 through February 18, 2020. The program...
Kenneth Rainin Foundation Awards Over $2 Million To Advance IBD Research
October 22, 2019 10:55 ET
|
Kenneth Rainin Foundation
Oakland, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation has awarded $2.2 million through its Innovator Awards to advance Inflammatory Bowel Disease (IBD) research and...
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
July 23, 2019 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Inflammatory Bowel Disease Treatment Market Size Worth US$ 21.3 Bn by 2026
July 10, 2019 11:00 ET
|
Acumen Research and Consulting
LOS ANGELES, July 10, 2019 (GLOBE NEWSWIRE) -- The global inflammatory bowel disease treatment market is estimated to grow at CAGR above 4.1 % over the forecast time frame 2019 to 2026 and reach the...
Metacrine Doses First Patient in 12-Week NASH Proof-of-Concept Trial with a Sustained FXR Agonist
July 09, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, July 09, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019
July 02, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients
May 29, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Rainin Foundation Seeks Novel, Collaborative Research Into Inflammatory Bowel Disease
May 28, 2019 10:55 ET
|
Kenneth Rainin Foundation
Oakland, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation invites proposals for its Synergy Awards program from June 3 through September 16, 2019. This funding opportunity...
Metacrine to Present at Jefferies 2019 Global Healthcare Conference
May 21, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...